TCGA-CF-A3MI-01A-11R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.15505913
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.500
- KRAS_SIGNALING_DN+0.450
- SPERMATOGENESIS+0.200
- ANGIOGENESIS+0.190
- COAGULATION+0.190
- MYOGENESIS+0.150
- KRAS_SIGNALING_UP+0.130
- APICAL_SURFACE+0.030
- ESTROGEN_RESPONSE_LATE+0.030
- ALLOGRAFT_REJECTION-0.040
Top 10 suppressed
- PROTEIN_SECRETION-0.650
- MYC_TARGETS_V1-0.630
- UNFOLDED_PROTEIN_RESPONSE-0.610
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.550
- MITOTIC_SPINDLE-0.550
- DNA_REPAIR-0.530
- MYC_TARGETS_V2-0.530
- MTORC1_SIGNALING-0.510
- ANDROGEN_RESPONSE-0.480
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG923 | — | — | 0.965 |
| 2 | TCGA-DK-A1A7-01A-11R-A13Y-07 | — | — | 0.963 |
| 3 | MNG1259 | — | — | 0.962 |
| 4 | MNG597 | — | — | 0.957 |
| 5 | MDT-AP-1190 | Med | Medulloblastoma | 0.956 |
| 6 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.956 |
| 7 | MNG436 | — | — | 0.956 |
| 8 | BS_23W9EPFE | Ganglioglioma | — | 0.955 |
| 9 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.949 |
| 10 | MNG1101 | — | — | 0.948 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.500 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.450 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.190 | Remibrutinib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |